Thursday, October 31, 2013
Publication and contact
Ribonucleotide reductase M2 (RRM2;
culture and mouse studies identified RRM2 inhibitors that could help treat
drug-resistant cancers. In cancer cell lines resistant to the ribonucleotide
reductase inhibitors hydroxyurea and Gemzar
the lead RRM2 inhibitor decreased proliferation compared with hydroxyurea or
gemcitabine alone. In mouse xenograft models of human ovarian cancer or
leukemia, the inhibitor caused tumor regression. Next steps could include
testing the inhibitor in additional cancer models.
Lilly and Co. markets Gemzar to treat breast, ovarian,
pancreatic and prostate cancers.
markets the ribonucleotide reductase inhibitor Clolar
to treat acute lymphoblastic leukemia (ALL).
Pharmaceuticals Inc.'s CALAA-01,
a small interfering RNA duplex targeting the M2 subunit of RRM2 and delivered
via the RNAi/oligonucleotide
nanoparticle delivery (RONDEL)
system, is in Phase I testing to treat solid tumors.
Published online Oct. 31, 2013
Patent and licensing status
Zhou, B. et al. Cancer
published online Sept. 26, 2013;
Contact: Yun Yen, City of Hope, Duarte, Calif.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]